Three randomized phase III trials have now conclusively proven that exposure to a PD-1
inhibitor prolongs survival in recurrent/metastatic (R/M) HNSCC, and it is clear that such …

Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of
tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx and …

Importance Novel approaches are needed to improve outcomes in patients with squamous
cell carcinoma of the oral cavity. Neoadjuvant immunotherapy given prior to surgery and …

Immunotherapy has changed the treatment landscape of Head and Neck cancer (HNC).
Different immune checkpoint inhibitors targeting PD-1/PD-L1 axis have been approved for …

Oral cancer is a type of cancer that develops in the mouth and is one of the deadliest
malignancies in the world. Currently surgical, radiation therapy, and chemotherapy are most …

Immunotherapy is radically changing the clinical management of patients affected by an
increasingly wide array of tumours. However, not all patients achieve long-term clinical …

Background: Surgical resection is the only curative treatment option for gastric cancer.
Despite widespread adoption of multimodality perioperative treatment strategies, 5-year …

Background The risk of delayed autoimmunity occurring months or years after
discontinuation of immunotherapy is frequently asserted in the literature. However, specific …

Purpose: In oropharyngeal squamous cell carcinoma (OPC), high CD8+ tumor-infiltrating
lymphocyte (CD8+ TIL) density confers improved prognosis. We compared neoadjuvant …

Recently, immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or
programmed cell death ligand-1 (PD-L1) monoclonal antibodies have improved the overall …